<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10098761</article-id><article-id pub-id-type="pmc">2362232</article-id><article-id pub-id-type="pii">6690194</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690194</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>European randomized study of prostate cancer screening: first-year results of the Finnish trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>M&#x000e4;&#x000e4;tt&#x000e4;nen</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Auvinen</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Stenman</surname><given-names>U-H</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Rannikko</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Tammela</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Aro</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Juusela</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Hakama</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff8">8</xref></contrib><aff id="aff1">Finnish Cancer Registry, Liisankatu 21 B, Helsinki, FIN-00170, Finland</aff><aff id="aff2">Radiation and Nuclear Authority, Helsinki, Finland</aff><aff id="aff3">Department of Clinical Chemistry, Helsinki University Central Hospital, Helsinki, Finland</aff><aff id="aff4">Department of Urology, Helsinki University Central Hospital, Helsinki, Finland</aff><aff id="aff5">Department of Urology, Tampere University Hospital, Tampere, Finland</aff><aff id="aff6">Department of Surgery, Helsinki City Hospital, Helsinki, Finland</aff><aff id="aff7">Department of Surgery, Jorvi Hospital, Espoo, Finland</aff><aff id="aff8">Tampere School of Public Health, University of Tampere, Tampere, Finland</aff></contrib-group><pub-date pub-type="ppub"><month>3</month><year>1999</year></pub-date><volume>79</volume><issue>7-8</issue><fpage>1210</fpage><lpage>1214</lpage><history><date date-type="received"><day>06</day><month>03</month><year>1998</year></date><date date-type="rev-recd"><day>09</day><month>09</month><year>1998</year></date><date date-type="accepted"><day>25</day><month>09</month><year>1998</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 1999 Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Approximately 20 000 men 55&#x02013;67 years of age from two areas in Finland were identified from the Population Registry and randomized either to the screening arm (1/3) or the control arm (2/3) of a prostate cancer screening trial. In the first round, the participation rate in the screening arm was 69&#x00025;. Of the 5053 screened participants, 428 (8.5&#x00025;) had a serum prostate-specific antigen (PSA) concentration of 4.0 ng/ml or higher, and diagnostic examinations were performed on 399 of them. A total of 106 cancers were detected among them corresponding to a positive predictive value of 27&#x00025;, which is comparable with mammography screening for breast cancer. The prostate cancer detection rate based on a serum PSA concentration of 4.0 ng ml<sup>&#x02212;1</sup> or higher was 2.1&#x00025;. Approximately nine out of ten screen-detected prostate cancers were localized (85&#x00025; clinical stage T1&#x02013;T2) and well or moderately differentiated (42&#x00025; World Health Organization (WHO) grade I and 50&#x00025; grade II), which suggests a higher proportion of curable cancers compared with cases detected by other means. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>screening</kwd><kwd>prostate neoplasms</kwd><kwd>randomized controlled trials</kwd><kwd>prostate-specific antigen</kwd></kwd-group></article-meta></front></article>
